Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Small earthquake felt in Wellington regionUS to build temporary port to deliver Gaza aidSmall earthquake felt in Wellington regionGovernment's targets: 'Where is the action behind these?'Whale song mystery solved by scientistsMore videos of Kiwi hostage Philip Mehrtens in Papua warn against Indonesian military air strikesUS to build temporary port to deliver Gaza aidFour things to watch out for as Americans votePublic servants on edge over nerveGulf Harbour body: Homicide investigation launched, public asked to help identify victim
1.8896s , 6503.03125 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Global Gleam news portal